Ipsen: Carcinoma trials

The registry lists 13 Carcinoma studies with Ipsen as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 2Phase 3 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell CarcinomaRecruitingNCT03787602Phase 1/2
• A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric CancersCompletedNCT01743469Phase 2Results posted
• A Study to Collect Pre-existing Data on the Administration of Cabozantinib in Participants With Advanced Renal Cell Carcinoma (aRCC) Who Initiated Cabozantinib in 2nd Line in a Real-life Clinical Setting in France.CompletedNCT05444933
• Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing CombinationCompletedNCT04957160
• Real-world Treatment Patterns and Outcomes Among aRCC Patients on Cabozantinib or Axitinib in EnglandCompletedNCT04637204
• Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.WithdrawnNCT04609800
• Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint InhibitorsCompletedNCT04353765
• Post-marketing Surveillance on the Safety of CabometyxTM in Korean PatientsCompletedNCT03776123
• Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.CompletedNCT03744585
• Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCCCompletedNCT03699579
• A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UKCompletedNCT03696407
• Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell CarcinomaCompletedNCT03419572
• Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal CarcinomatosisCompletedNCT00216372Phase 3